Oligodendroglioma

Oligodendrogliomas are a type of brain tumours that are believed to originate from the oligodenrocytes of the brain or from a glial precursor cell. Similar to other gliomas, they can be divided into a low-grade and an anaplastic variant.

 

Please note that the following threads of our forum are currently only available in German language.

Histology of Oligodendroglioma

    • oligodendroglioma (WHO grade II)
    • anaplastic oligodendroglioma (WHO grade III)

     

    Epidemiology of Oligodendroglioma

     

    • peak age between 35 and 50
    • in childhood around 10
    • men are a little more often affected

     

    Symptoms of Oligodendroglioma

     

    • mainly epileptic seizures as initial sign
    • symptoms of cerebral pressure (headache, nausea, emesis)
    • less frequently neurological deficits and organic psycho syndrome
    • locally caused symptoms related to increased growth


    Diagnosing Oligodendroglioma

    • diagnosis with MRT and CT
    • sometimes biopsy to confirm diagosis
    • CT to detect frequently occuring calcifications
    • heterogenous enhancement of contrast agent
    • sometimes slight enhancement of contrast agent in WHO grade II
    • diffusely infiltrating in surrounding tissue
    • often hemorrhages
    • main localisation: frontal- and temporal lobe of cerebrum

     

    Therapy of Oligodendroglioma

     

    • as complete as possible surgical removal of brain tumour
    • radiotherapy after partial surgeries and anaplastic tumours
    • chemotherapy in progressive and anaplastic tumours
    • chemotherapy also discussed for grade II tumours


    Therapy of Recurrent Oligodendroglioma

    • renewed surgery of brain tumour
    • (second) irradiation
    • chemotherapy with different agents, e.g. PCV-scheme
    • experimental therapeutic approaches

     

    Aftercare of Oligodendroglioma

     

    • first check-up 6 weeks after therapy (MRI with contrast agent)
    • WHO grade II: check-up every three months, if results are constant every 6 to 12 months
    • WHO grade III: every three months (MRI with contrast agent)

     

    Course of Oligodendroglioma

     

    • growth characteristic depends on WHO grade
    • high rate of recurrence
    • development from WHO grade II to WHO grade III possible

      Latest News

      Methadon in der Gliomtherapie?

      Retrospektive Untersuchung von Gliompatienten

       > more

      Hirntumor-Informationstag

      Am 13.05.2017 findet der nächste Hirntumor-Informationstag in Köln statt.

       > more

      Experten-Interview

      Die Brainstorm-Redaktion traf SNO-Präsident Prof. Dr. Antonio Chiocca exklusiv zum Gespräch

       > more